Deshengji Pharmaceutical

Deshengji Pharmaceutical, a subsidiary of InventisBio, is a clinical-stage biopharmaceutical company based in Beijing, China, focused on the discovery and development of innovative small molecule therapeutics. The company targets high-impact areas including oncology and metabolic diseases, leveraging its proprietary drug discovery platform. Its portfolio features Befotertinib, an EGFR inhibitor approved for non-small cell lung cancer, and Garsorasib, a KRAS G12C inhibitor currently in the NDA stage. Additionally, Deshengji is advancing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a URAT1 inhibitor for gout. The company maintains a strong presence in the Chinese biotech ecosystem through strategic partnerships and a robust clinical pipeline.